Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 428-432

  Yuan, L ^a   Yao, L ^a   Zhao, L ^a   Xia, L ^a   Shen, H ^a   Lu, J ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Dermatomyositis; Interleukin 33; Polymyositis; Soluble ST2

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INTERLEUKIN 33; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; MI 2 ANTIBODY; PREDNISONE; PROTEIN ANTIBODY; ST2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATOMYOSITIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VISUAL ANALOG SCALE;

ADULT; AGED; CASE-CONTROL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMYOSITIS; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX;

EID: 84878361426     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. CHACKERIAN AA, OLDHAM ER, MURPHY EE, SCHMITZ J, PFLANZ S, KASTELEIN RA: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179: 2551-5.
2. BERGERS G, REIKERSTORFER A, BRASELMANN S, GRANINGER P, BUSSLINGER M: Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membranebound proteins related to the IL-1 receptor. EMBO J 1994; 13: 1176-88.
3. ASHLEY M: Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22.
4. ALI S, HUBER M, KOLLEWE C, BISCHOFF SC, FALK W, MARTIN MU: IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007; 104: 18660- 5.
5. HONG YS, MOON SJ, JOO YB et al.: Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26: 1132-9.
6. KAMEKURA R, KOJIMA T, TAKANO K, GO M, SAWADA N, HIMI T: The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 2012; 42: 218-28.
7. MOK MY, HUANG FP, IP WK et al.: Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49: 520-7.
8. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
9. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
10. SULTAN SM, ALLEN E, ODDIS CV et al.: Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008; 58: 3593-9.
11. DALAKAS MC, HOHLFELD R: Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
12. ISHII W, MATSUDA M, SHIMOJIMA Y, ITOH S, SUMIDA T, IKEDA S: Flow cytometric analysis of lymphocyte subpopulations and TH1/ TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008; 47: 1593-9.
13. PAGE G, CHEVREL G, MIOSSEC P: Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004; 50: 199-208.
14. SHEN H, XIA L, LU J, XIAO W: Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011; 40: 217-20.
15. DÍAZ-JIMÉNEZ D, NÚÑEZ LE, BELTRÁN CJ et al.: Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011; 17: 2181-90.
16. MUELLER T, DIEPLINGER B, GEGENHUBER A, POELZ W, PACHER R, HALTMAYER M: Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752-6.
17. MILOVANOVIC M, VOLAREVIC V, RADOSAVLJEVIE G et al.: IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52: 89-99.
18. XIANGYANG Z, LUTIAN Y, LIN Z, LIPING X, HUI S, JING L: Increased levels of interleukin- 33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012; 58: 6-9.